
Kawasaki Disease (KD) Care Guideline






Reassess the appropriateness of Care Guidelines as condition changes and 24 hrs after admission. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates.

1 of 3

Kawasaki Disease (KD) Care Guideline



- Kids Health
 - o Kawasaki Disease for Parents
- Lexicomp
 - Kawasaki Disease
 - Kawasaki Disease Discharge Instructions

Kawasaki Disease (KD) Care Guideline



Kawasaki Disease (KD) Care Guideline References

- Burns, J. C., Roberts, S. C., Tremoulet, A. H., He, F., Printz, B. F., Ashouri, N., . . . Jain, S. (2021). Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE: a randomized, multicentre comparative effectiveness trial. *The Lancet. Child & Adolescent Health*, 5(12), 852-861. https://doi.org/10.1016/S2352-4642(21)00270-4 (Level II)
- McCrindle, B. W., Rowley, A. H., Newburger, J. W., Burns, J. C., Bolger, A. F., Gewitz, M., . . . Pahl, E. (2017). Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*, 135(17), e927-e999. https://doi.org/10.1161/ CIR.00000000000484 (Level V)
- Vande Casteele, N., Oyamada, J., Shimizu, C., Best, B. M., Capparelli, E. V., Tremoulet, A. H., & Burns, J. C. (2018). Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. *Clinical Pharmacokinetics*, 57(12), 1593-1601. https://doi.org/10.1007/s40262-018-0653-6 (Level I)